Evogene Ltd. EVGN EVGN, an Israeli biotech connected to the cannabis industry through its subsidiary Canonic Ltd., released fourth-quarter and full-year 2019 financial results Wednesday.
Evogene posted quarterly revenue of $100,000 versus $600,000 in the prior year period.
For the full year, the company posted revenue of $800,000 down from $1.8 million in 2018.
Evogene reported a gross profit of $35,000 for the quarter versus $8,000 in the comparable quarter of 2018.
The company's 2019 loss of $19 million is lower than its $21-million loss in 2018.
In the fourth quarter of 2019 alone, Evogene had a loss of $6.7 million versus a loss of $5.8 million in the same quarter of 2018.
"2019 has been a turning point year in the life of the company, with the completion of the organizational plan introduced at the beginning of 2018,” Ofer Haviv, Evogene's President and CEO, said in a statement.
"The rationale behind this change was to capture the value of our diverse capabilities in computational biology. To this end, we established dedicated subsidiaries in specific markets, while at the heart of all activities is Evogene's unique technology, the CPB (Computational Predictive Biology) platform serving as the subsidiaries' core technological advantage.”
Evogene's milestones in 2019 included Corteva's investment in Lavie Bio, which Evogene said has made progress in bio-stimulants for a wheat program and in bio-fungicide and bio-insecticide product programs; advancements in Biomica's immuno-onocology program; and the beginning of the development of Canonic's cannabis varieties.
The stock was down 6.51% at $1.28 at the time of publication Wednesday.
Related Links:
Agribiotech Evogene Launches Medical Cannabis Subsidiary, CEO Expects 'Significant Impact' In Sector
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
The Benzinga Cannabis Capital Conference is coming to Florida
The Benzinga Cannabis Capital Conference is returning to Florida, in a new venue in Hollywood, on April 16 and 17, 2024. The two-day event at The Diplomat Beach Resort will be a chance for entrepreneurs, both large and small, to network, learn and grow. Renowned for its trendsetting abilities and influence on the future of cannabis, mark your calendars – this conference is the go-to event of the year for the cannabis world.
Get your tickets now on bzcannabis.com – Prices will increase very soon!